JPMorgan analyst Jessica Fye raised the firm’s price target on Cerevel Therapeutics (CERE) to $45 from $25 and keeps a Neutral rating on the shares to reflect the pending acquisition by AbbVie (ABBV).
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CERE:
- Karuna downgraded, Arm target raised: Wall Street’s top analyst calls
- Reviva may be most undervalued in neurology, says H.C. Wainwright
- Cerevel Therapeutics price target raised to $45 from $30 at Wells Fargo
- Cerevel Therapeutics downgraded to Hold from Buy at Jefferies
- Cerevel Therapeutics just downgraded at Stifel, here’s why